Biosimilars, clinical management and incentives

Biosimilars/Research | Posted 12/11/2021 post-comment0 Post your comment

The aim of a study carried out by Spanish researchers was to identify and analyse policies applied in the health services to enhance uptake of biosimilars in the framework of clinical management settings [1]. Incentives, both financial and non-financial, were of particular interest for the authors. They reviewed the relevant experiences developed in different high-income countries with advanced healthcare systems. In addition, they investigated barriers to the implementation of these policies in Spain.

Meds Cost Euros 1 V13L06

The authors consider this to be a pioneering study since very little research literature can be found on the subject. After an introductory chapter explaining the motivation for this work, chapter two is dedicated to the concept of economic incentives and to the review of the main findings of the economic literature, paying attention to pay for performance and gainsharing arrangements. The final section covers incentives to improve prescription of medicines by doctors.

There are two chapters dealing with the development of clinical management in general and in Spain. The next chapter is dedicated to the barriers that exist in Spain to the development of incentives for biosimilars in the framework of clinical management. Chapter six summarizes the systematic literature search carried for the purposes of the study. Chapter seven describes experiences of the implementation of incentive schemes for biosimilars in the US, Denmark, France, Germany, Italy, UK and Canada.

This is followed by the development and main ideas of a multidisciplinary focus group of experts. On the basis of the study, and some guiding questions, the group discussions led to a number of contributions that have been included in the recommendations collected in the ninth chapter.

The study also includes an executive summary at the beginning and several annexes at the end.

Conflict of interest
The authors of the book [1] did not provide any conflict of interest statement. The book was unconditionally funded by the Spanish Association of Biosimilar Medicines, BIOSIM.

Abstracted by Félix Lobo, Profesor Emérito, Department of Economics, University Carlos III de Madrid and Funcas, ES-28903 Getafe, Madrid, Spain.

Editor’s comment
Readers interested to learn more about policies for biosimilars are invited to visit to view the following manuscripts published in GaBI Journal:

Local policies on biosimilars: are they designed to optimize use of liberated resources?

Policy recommendations for a sustainable biosimilars market: lessons from Europe

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
2.0 – CiteScoreTracker 2021 (Last updated on 5 October 2021)

Submit a manuscript to GaBI Journal

Related articles
Targets and incentives to encourage use of biosimilars

International prescribing incentives for biosimilars


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Los datos apoyan la intercambiabilidad de los biosimilares de la UE

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. Lobo F, Del Rio I. Gestión clínica, incentivos y biosimilares (Biosimilars, Clinical Management and Incentives). 2020. Ediciones Díaz de Santos. Madrid.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Biosimilars: Promises made. Promises kept?
Biosimilars/Research Posted 19/11/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010